BR112017009440A2 - uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) - Google Patents
uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)Info
- Publication number
- BR112017009440A2 BR112017009440A2 BR112017009440A BR112017009440A BR112017009440A2 BR 112017009440 A2 BR112017009440 A2 BR 112017009440A2 BR 112017009440 A BR112017009440 A BR 112017009440A BR 112017009440 A BR112017009440 A BR 112017009440A BR 112017009440 A2 BR112017009440 A2 BR 112017009440A2
- Authority
- BR
- Brazil
- Prior art keywords
- host disease
- versus host
- graft versus
- inhibitor
- gvhd
- Prior art date
Links
- 108010077544 Chromatin Proteins 0.000 title 1
- 208000009329 Graft vs Host Disease Diseases 0.000 title 1
- 210000003483 chromatin Anatomy 0.000 title 1
- 208000024908 graft versus host disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 101150090105 Ezh2 gene Proteins 0.000 abstract 2
- 208000017760 chronic graft versus host disease Diseases 0.000 abstract 2
- 229940121649 protein inhibitor Drugs 0.000 abstract 2
- 239000012268 protein inhibitor Substances 0.000 abstract 2
- UMZWNADQRDCKII-UHFFFAOYSA-N 2-[5-(5-bromo-2-oxoindol-3-yl)-4-hydroxy-2-sulfanylidene-1,3-thiazol-3-yl]butanedioic acid Chemical compound OC(=O)CC(C(O)=O)n1c(O)c(sc1=S)C1=c2cc(Br)ccc2=NC1=O UMZWNADQRDCKII-UHFFFAOYSA-N 0.000 abstract 1
- 229940096923 Bcl6 inhibitor Drugs 0.000 abstract 1
- 102000001805 Bromodomains Human genes 0.000 abstract 1
- 108050009021 Bromodomains Proteins 0.000 abstract 1
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 abstract 1
- 102000013538 Proto-Oncogene Proteins c-bcl-6 Human genes 0.000 abstract 1
- 108010090920 Proto-Oncogene Proteins c-bcl-6 Proteins 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076358P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/059551 WO2016073903A1 (en) | 2014-11-06 | 2015-11-06 | Use of compositions modulating chromatin structure for graft versus host disease (gvhd) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017009440A2 true BR112017009440A2 (pt) | 2017-12-19 |
Family
ID=55909890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017009440A BR112017009440A2 (pt) | 2014-11-06 | 2015-11-06 | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190000860A1 (enExample) |
| EP (1) | EP3215160A4 (enExample) |
| JP (1) | JP2017533922A (enExample) |
| KR (1) | KR20170098808A (enExample) |
| CN (1) | CN107249593A (enExample) |
| AU (1) | AU2015342895A1 (enExample) |
| BR (1) | BR112017009440A2 (enExample) |
| CA (1) | CA2966336A1 (enExample) |
| WO (1) | WO2016073903A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3157527T3 (pl) | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| WO2016073956A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| CN109069508A (zh) | 2016-04-22 | 2018-12-21 | 达纳-法伯癌症研究所股份有限公司 | Ezh2抑制剂及其用途 |
| CN110191722B (zh) | 2017-01-19 | 2022-03-01 | 第一三共株式会社 | 用于治疗htlv-1相关性脊髓病的药物组合物 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| PT4043466T (pt) | 2018-01-31 | 2024-10-14 | Mirati Therapeutics Inc | Inibidores de prc2 |
| CN108685880A (zh) * | 2018-04-16 | 2018-10-23 | 广东省人民医院(广东省医学科学院) | Bcl-6小分子抑制剂用于制备预防或治疗cGVHD的药物 |
| WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| AU2019409868A1 (en) * | 2018-12-21 | 2021-07-08 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating inflammation |
| EP3959214A1 (en) | 2019-04-22 | 2022-03-02 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| EP3980422A1 (en) | 2019-06-05 | 2022-04-13 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| CN112341390B (zh) * | 2019-08-07 | 2022-08-23 | 四川大学 | 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途 |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
| EP4568946A1 (en) * | 2022-08-09 | 2025-06-18 | Dana-Farber Cancer Institute, Inc. | Macrocyclic bcl6 degraders |
| WO2024211684A1 (en) * | 2023-04-06 | 2024-10-10 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE305777T1 (de) * | 1999-07-16 | 2005-10-15 | Kissei Pharmaceutical | Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation |
| WO2008066887A2 (en) * | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| KR20080107050A (ko) * | 2007-06-05 | 2008-12-10 | 울산대학교 산학협력단 | 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
| US8637509B2 (en) * | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
| US20120014979A1 (en) * | 2010-07-16 | 2012-01-19 | Alexander Dent | Use of bcl6 inhibitors for treating autoimmune diseases |
| JP2014511389A (ja) * | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換６，５−縮合二環式ヘテロアリール化合物 |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| KR20140095073A (ko) * | 2011-11-04 | 2014-07-31 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 치료 방법 |
| JP2015508780A (ja) * | 2012-02-17 | 2015-03-23 | アンサン バイオファーマ，インコーポレイテッド | 免疫不全患者のインフルエンザ及びパラインフルエンザウイルスを処置するための方法、化合物、及び組成物 |
| WO2014155301A1 (en) * | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
-
2015
- 2015-11-06 WO PCT/US2015/059551 patent/WO2016073903A1/en not_active Ceased
- 2015-11-06 BR BR112017009440A patent/BR112017009440A2/pt not_active Application Discontinuation
- 2015-11-06 JP JP2017525115A patent/JP2017533922A/ja active Pending
- 2015-11-06 AU AU2015342895A patent/AU2015342895A1/en not_active Abandoned
- 2015-11-06 KR KR1020177014969A patent/KR20170098808A/ko not_active Withdrawn
- 2015-11-06 CA CA2966336A patent/CA2966336A1/en not_active Abandoned
- 2015-11-06 CN CN201580066388.8A patent/CN107249593A/zh active Pending
- 2015-11-06 US US15/524,707 patent/US20190000860A1/en not_active Abandoned
- 2015-11-06 EP EP15856340.3A patent/EP3215160A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015342895A1 (en) | 2017-05-18 |
| CN107249593A (zh) | 2017-10-13 |
| CA2966336A1 (en) | 2016-05-12 |
| WO2016073903A1 (en) | 2016-05-12 |
| JP2017533922A (ja) | 2017-11-16 |
| KR20170098808A (ko) | 2017-08-30 |
| EP3215160A1 (en) | 2017-09-13 |
| US20190000860A1 (en) | 2019-01-03 |
| EP3215160A4 (en) | 2018-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017009440A2 (pt) | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| DOP2020000252A (es) | Inhibidores de proteina tirosina fosfatasa y sus métodos de uso | |
| BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
| MX2019012032A (es) | Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3). | |
| BR112016028066A2 (pt) | composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira | |
| CL2018000853A1 (es) | Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer. | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
| CR20170219A (es) | Inhibidores del bromodominio | |
| MX2020012064A (es) | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. | |
| AU2016304856A8 (en) | Mechanism of resistance to BET bromodomain inhibitors | |
| BR112015030385A8 (pt) | composto, composto para uso e composição farmacêutica | |
| CL2021000650A1 (es) | Moduladores de la expresión de pnpla3 | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| BR112018012177A2 (pt) | ?moduladores de hidantação de canais kv 3? | |
| MX2021006347A (es) | Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2. | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| MX2022006932A (es) | Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control. | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| MX2021002668A (es) | Plataforma de virus oncolitico para tratar el cancer hematologico. | |
| BR112019000635A2 (pt) | inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| BR112022001985A2 (pt) | Métodos para tratamento de câncer pelo uso de inibidores do eixo pd-1 e anticorpos anti-periostina | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |